S124: Adverse Events Following Covid-19 Vaccination in Transfusion-Dependent -Thalassemia Patients

Delaporta, Polyxeni; Kyriakopoulou, Dimitra; Ioakeimidou, Natalia; Solomou, E; Binenbaum, I; Toutoudaki, Konstantina; Chatzielefteriou, M.-I.; Papassotiriou, Ioannis; Kattamis, Antonis

doi:10.1097/01.hs9.0000821464.52797.65

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An acute hemolytic crisis was observed in 2 patients after receiving the Pfizer/BioNTech vaccine by Delaporta et al [22]. Both patients had a history of hemolytic crises as well.…”

Section: Discussionmentioning

confidence: 99%

Adverse Effects of COVID-19 Vaccination in Patients with Transfusion-Dependent Thalassemia: An Observational Study from a Tertiary Care Center in Punjab, India

Kakkar¹,

Jain²,

Jain³

et al. 2023

Acta Haematol

View full text Add to dashboard Cite

Vaccination against SARS-CoV2 is the most important weapon in the arsenal in the battle against COVID-19. There is concern about an increased risk of adverse effects in patients with transfusion-dependent thalassemia (TDT), which affects vaccine acceptance. A predesigned questionnaire was used to evaluate adverse effects (local/systemic within 90 days after vaccination) in participants >18 years of age with TDT. A total of 100 patients received 129 vaccine doses. The mean age of the patients was 24.3 ± 5.7 years and M: F ratio of 1.6:1. Covishield (Serum Institute of India) was administered to 89% of the participants and Covaxin (Bharat Biotech Limited) to 11% of the participants. Adverse effects were documented in 62% of the respondents and were more pronounced after the first dose (52%) compared to the second dose (9%). The most frequent adverse effects were pain at the injection site (43%) and fever (37%). All adverse effects were mild and none of the participants required hospitalization. There were no differences in adverse effects among different vaccines, the presence or absence of comorbidities, blood groups, or ferritin levels. The SARS-CoV2 vaccine appears to be safe in patients with TDT.

show abstract

“…An acute hemolytic crisis was observed in 2 patients after receiving the Pfizer/BioNTech vaccine by Delaporta et al [22]. Both patients had a history of hemolytic crises as well.…”

Section: Discussionmentioning

confidence: 99%

Adverse Effects of COVID-19 Vaccination in Patients with Transfusion-Dependent Thalassemia: An Observational Study from a Tertiary Care Center in Punjab, India

Kakkar¹,

Jain²,

Jain³

et al. 2023

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Since people with thalassemia or SCD are more vulnerable to COVID-19 infection, they have a higher risk of hospitalization, mortality, and complications ( 36 ). Although vaccination enables immunity in both thalassemia and patients with SCD, some people with thalassemia showed vaccine-related adverse effects, including decreased hemoglobin levels and hemolysis ( 37 ). Those patients should be followed up closely following the vaccination because of vaso-occlusive crisis (VOC) along with increased levels of white blood cells (WBC) and liver enzyme; in contrast, a significant decrease in hemoglobin and platelet levels has been observed after COVID-19 vaccination ( 38 ).…”

Section: The Impact Of Covid-19 Vaccines On People With Hematological...mentioning

confidence: 99%

People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVID-19 vaccination

Aydemir

Ulusu²

2023

Front. Med.

View full text Add to dashboard Cite

show abstract

Tozinameran

2022

Reactions Weekly

View full text Add to dashboard Cite

S124: Adverse Events Following Covid-19 Vaccination in Transfusion-Dependent -Thalassemia Patients

Cited by 3 publications

References 0 publications

Adverse Effects of COVID-19 Vaccination in Patients with Transfusion-Dependent Thalassemia: An Observational Study from a Tertiary Care Center in Punjab, India

Adverse Effects of COVID-19 Vaccination in Patients with Transfusion-Dependent Thalassemia: An Observational Study from a Tertiary Care Center in Punjab, India

People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVID-19 vaccination

Tozinameran

Contact Info

Product

Resources

About